The presence of inflammation and demyelination in a central nervous system (CNS) biopsy points towards a limited, yet heterogeneous group of pathologies, of which multiple sclerosis (MS) represents one of the principal considerations. Inflammatory demyelination has also been reported in patients with clinically suspected primary central nervous system lymphoma (PCNSL), especially when steroids had been administered prior to biopsy acquisition. The histopathological changes induced by corticosteroid treatment can range from mild reduction to complete disappearance of lymphoma cells. It has been proposed that in the absence of neoplastic B cells, these biopsies are indistinguishable from MS, yet despite the clinical relevance, no histological studies have specifically compared the two entities. In this work, we analyzed CNS biopsies from eight patients with inflammatory demyelination in whom PCNSL was later histologically confirmed, and compared them with nine well defined early active multiple sclerosis lesions. In the patients with steroid-treated PCNSL (ST-PCNSL) the interval between first and second biopsy ranged from 3 to 32 weeks; all of the patients had received corticosteroids before the first, but not the second biopsy. ST-PCNSL patients were older than MS patients (mean age: ST-PCNSL: 62 6 4 years, MS: 30 6 2 years), and histological analysis revealed numerous apoptoses, patchy and incomplete rather than confluent and complete demyelination and a fuzzy lesion edge. The loss of Luxol fast blue histochemistry was more profound than that of myelin proteins in immunohistochemistry, and T cell infiltration in ST-PCNSL exceeded that in MS by around fivefold (P 5 0.005). Our data indicate that in the presence of extensive inflammation and incomplete, inhomogeneous demyelination, the neuropathologist should refrain from primarily considering autoimmune inflammatory demyelination and, even in the absence of lymphoma cells, instigate close clinical follow-up of the patient to detect recurrent lymphoma. 
Abstract
The presence of inflammation and demyelination in a central nervous system (CNS) biopsy points towards a limited, yet heterogeneous group of pathologies, of which multiple sclerosis (MS) represents one of the principal considerations. Inflammatory demyelination has also been reported in patients with clinically suspected primary central nervous system lymphoma (PCNSL), especially when steroids had been administered prior to biopsy acquisition. The histopathological changes induced by corticosteroid treatment can range from mild reduction to complete disappearance of lymphoma cells. It has been proposed that in the absence of neoplastic B cells, these biopsies are indistinguishable from MS, yet despite the clinical relevance, no histological studies have specifically compared the two entities. In this work, we analyzed CNS biopsies from eight patients with inflammatory demyelination in whom PCNSL was later histologically confirmed, and compared them with nine well defined early active multiple sclerosis lesions. In the patients with steroid-treated PCNSL (ST-PCNSL) the interval between first and second biopsy ranged from 3 to 32 weeks; all of the patients had received corticosteroids before the first, but not the second biopsy. ST-PCNSL patients were older than MS patients (mean age: ST-PCNSL: 62 6 4 years, MS: 30 6 2 years), and histological analysis revealed numerous apoptoses, patchy and incomplete rather than confluent and complete demyelination and a fuzzy lesion edge. The loss of Luxol fast blue histochemistry was more profound than that of myelin proteins in immunohistochemistry, and T cell infiltration in ST-PCNSL exceeded that in MS by around fivefold (P 5 0.005). Our data indicate that in the presence of extensive inflammation and incomplete, inhomogeneous demyelination, the neuropathologist should refrain from primarily considering autoimmune inflammatory demyelination and, even in the absence of lymphoma cells, instigate close clinical follow-up of the patient to detect recurrent lymphoma.
INTRODUCTION
Demyelination, defined as the loss of myelin with preservation of the axonal lattice, is a highly characteristic feature in diagnostic neuropathology and points to a narrow group of diseases of infectious, metabolic, toxic and especially autoimmune etiology such as acute disseminated encephalomyelitis, neuromyelitis optica, and most prominently, multiple sclerosis (MS). In addition, CNS biopsies of patients with primary CNS lymphoma treated with corticosteroids prior to biopsy acquisition (ST-PCNSL) may lack a demonstrable neoplastic B cell component and hence present with inflammation and demyelination as the dominant pathologic features (2, 6, 9, 16) . This type of lesion is often referred to as 'sentinel lesion', after the original report of four cases by Alderson and coworkers (2) , and can mislead the neuropathologist to a diagnosis of classical inflammatory demyelinating disease. A timely and correct diagnosis is essential for adequate treatment of the patients, yet reliable discrimination between these two entities is generally considered not possible on a histological basis, even though neither formal criteria nor specific studies addressing this question exist (3, (13) (14) (15) . Recently, we and others alluded to the presence of substantial T cell infiltration and a distinct demyelination pattern in a cohort of ST-PCNSL patients (4, 6, 9) . In this study, we elaborate on this observation by performing a direct comparison with early demyelinating MS lesions, and put forward diagnostic hallmarks to differentiate demyelination and inflammation caused by autoimmunity from that accompanying steroid-treated primary CNS lymphoma.
MATERIALS AND METHODS

Patient selection
The database of the Institute of Neuropathology, University Medical Center (UMG), G€ ottingen, Germany, was retrospectively screened for patients who underwent CNS biopsy first evaluated at our institute or received for reference neuropathological examination between January 2006 and December 2014. Different inclusion criteria were established for three independent cohorts: steroidtreated primary CNS lymphoma (ST-PCNSL), primary CNS lymphoma of diffuse large B cell type (PCNSL) and multiple sclerosis (MS). The ST-PCNSL group included patients who underwent at least two sequential biopsies. The first, acquired after treatment with systemic glucocorticoids, had received an initial neuropathological diagnosis of an inflammatory or inflammatory demyelinating process while the second, obtained at a later time point, was diagnosed as a diffuse large B cell lymphoma. Three male and 5 female patients with a mean age of 62 6 4.4 years at the time of first biopsy were included. The mean time between the two biopsies was 2.9 6 1 months. Clinical data and radiological findings are summarized in Supporting Information Table S1 .
For the MS cohort we aimed at minimizing the risk of including demyelinating pathologies other than MS. For this purpose we included patients with a histological diagnosis of MS and a characteristic clinical course (Supporting Information Table S2 ). In this cohort, biopsy was performed to exclude concomitant pathologies such as glioma, lymphoma or infection. Only cases with sufficient tissue and an initial neuropathological report corresponding to an early active MS lesion (5) were included. Nine patients (4 male; 5 female) with a mean age of 30 6 2 years at the time of biopsy were included in the study. A summary of radiological and clinical data can be found in Supporting Information Table S2 .
The PCNSL group consisted of 19 patients (4 male; 15 female) with a histological diagnosis of primary CNS lymphoma of diffuse large B-cell type established at our institute. None of the patients had received corticosteroid therapy at any time point before biopsy acquisition. The mean age at diagnosis was 67.6 6 3.3 years. In 14 patients the initial clinical diagnostic suspicion was PCNSL, a primary brain tumor being the most frequent clinical/radiological differential diagnosis. The study protocol was approved by the local ethics committee.
Tissue sampling, histology and immunohistochemistry
Formalin-fixed, paraffin-embedded CNS biopsy material was obtained from the archives of the Institute of Neuropathology G€ ottingen. Only cases with sufficient available tissue for histological analysis were included. Tissue sections (thickness: 2-5 mm) were prepared and stained using standard histochemical and immunohistochemical techniques (24) . Antibody dilutions and sources are listed in Table 1 .
Image acquisition, processing and morphometric analysis
Color microphotographs of tissue sections were acquired with an inverted brightfield microscope (BZ-9000E, KEYENCE, NeuIsenburg, Germany) using the BZ-II Analyzer software (KEY-ENCE) and were merged into a mosaic image using the BZ-II Viewer software v2.2 (KEYENCE). Cell densities were determined by dividing the total number of cells in lesion areas by the total lesion area, and are expressed as cells/mm 2 . Individual cells were manually counted using the cell counter plugin of the image analysis software FIJI (19) . To determine the extent of acute axonal damage, amyloid precursor protein (APP) stained spheroids were manually counted in 5 randomly selected microscopic fields in both ST-PCNSL and MS lesions at 4003 magnification. Their density is given as the median number of APP 1 spheroids/mm 2 . The axonal density was determined by Bielschowsky silver impregnation. Point sampling of 8 microscopic fields was performed using an ocular 25-point grid at 10003 magnification. The number of axons crossing the grid points was counted in random areas within the lesion or the periplaque normal appearing white matter (NAWM). In the periplaque NAWM, the number of axons crossing the grid points was averaged between all samples containing NAWM and set to 100%. The axonal reduction was calculated as percentage of the axonal density within the lesion compared with the NAWM.
Statistical analysis
Statistical analysis and plotting (23) were performed using the R software (21) . For comparisons of cell densities between two groups an unpaired t-test was used. Pearson correlations among candidate predictor variables were done using the corrplot package (22) . Binary logistic regression and related indexes were computed using the rms package (10) . Missing values for logistic regression analysis were imputed using the transcan function of the Hmisc package (11) . The complete dataset and an explanatory script of the analysis are provided in Supporting Information Appendix S1. Unless otherwise stated, data represent mean values 6 standard error of the mean.
RESULTS
Inflammation and demyelination in ST-PCNSL biopsies
CNS biopsies of ST-PCNSL (n 5 8) revealed a hypercellular tissue with extensive perivascular and diffuse mononuclear infiltration and numerous foamy macrophages. Overt cellular pleomorphism, mitotic figures or tissue necrosis were not seen, but apoptotic nuclei were readily apparent (14.4 6 3.8 apoptoses/mm 2 ; n 5 8) ( Figure  1A ). Luxol fast blue (LFB) histochemistry evidenced a partial to complete myelin loss with fuzzy lesion borders. In 2 out of 8 cases, only small focal demyelination was observed. The pattern of demyelination in ST-PCNSL biopsies frequently consisted of pale, sparse and seemingly swollen or disrupted myelin sheaths next to and within areas of frank demyelination ( Figure 1B ). Frequently, myelin seemed substantially reduced but not entirely absent in LFB histochemistry. Interestingly, immunohistochemistry (IHC) with anti-MBP and other anti-myelin antibodies showed a less pronounced myelin loss than expected from LFB histochemistry (Figure 1C) . The axonal lattice was distended but relatively preserved ( Figure 1D and Supporting Information Figure S1 ). Immunolabelling with the pan-macrophage/microglia marker KiM1P revealed an infiltration of macrophages/activated microglia in a scattered distribution within the lesions ( Figure 1E and Supporting Information Figure S2 ). To aid lesion staging, the expression of MRP14, a calcium binding protein which is expressed in macrophages during the earliest stages of demyelinating activity (5) ; n5 8), most of which corresponded to T lymphocytes (Ki67/CD3: 8.3 6 4.0%; n 5 8), thus suggesting an inflammatory rather than a neoplastic origin of the lesion. Taken together, the histomorphological features observed in ST-PCNSL argued in favour of inflammatory demyelination as documented in the original neuropathological reports. However, a diffuse large B cell lymphoma (DLBCL) was histologically confirmed in a subsequent biopsy in all cases (Supporting Information Figure S3 ).
Increased T cell infiltration and incomplete demyelination allow a histological differentiation of ST-PCNSL from MS
ST-PCNSL biopsies were then compared with early active MS lesions, the main differential diagnosis of confluent inflammatory demyelination in routine neuropathological practice. Myelin loss in LFB histochemistry was prominent in both entities, yet in MS, demyelination was more thorough, and in the center of the majority of lesions, no or only few remaining LFB 1 fibers could be discerned (Figure 2) . A clearly defined sharp lesion border, often with a higher density of macrophages at the site of radial lesion expansion (1) was seen in 4 of the 9 patients but in none of the ST-PCNSL cases (Supporting Information Figures S2 and S4) . Also in MS, MRP14
1 macrophages were frequently accentuated at the actively demyelinating lesion rim, while showing a more diffuse distribution in ST-PCNSL (Supporting Information Figure S2 ).
Also by myelin immunohistochemistry, large, confluent areas of complete or near complete demyelination were characteristic for early MS lesions but not for ST-PCNSL. Interestingly in ST-PCNSL, the vessel walls appeared thickened and showed an intense staining for periodic acid Schiff (PAS), yet similar changes could not be demonstrated in MS (Figure 2) .
In both ST-PCNSL and MS lesions, we observed a reduction in axonal density within lesion areas of about 40-50% (MS: 52.48 6 4.36%, n 5 9; ST-PCNSL: 43.53 6 3.83%, n 5 6) as compared with areas of normal-appearing white matter in the respective biopsies. The extent of axonal loss, however, was not significantly different between the two entities (t-test, P 5 0.09) (Supporting Information Figure S1 ). Moreover, we did not observe differences in the density of axonal spheroids/mm 2 
density of CD3
1 lymphocytes as a sole predictor in a binary logistic regression model (Supporting Information Appendix S1). Data analysis revealed a significant effect of CD3 on diagnosis, v 2 (1) 5 14.51, P < 0.001, and the Somer's rank correlation index, D xy 5 0.88, showed an excellent ability of the model to discriminate between MS and ST-PCNSL biopsies. This indicates that extensive CD3
1 T lymphocyte infiltration should serve as a red flag in a biopsy specimen with inflammatory and demyelinating features. It should thus prevent the neuropathologist from diagnosing autoimmune inflammatory demyelination and stimulate close clinical follow-up to rapidly detect recurrent lymphoma.
Demyelination is not a common histological feature of classical diffuse large B cell lymphoma
Given the conspicuousness of demyelination in the ST-PCNSL cohort, we examined the myelination status of the CNS in diffuse large B cell lymphoma without previous steroid treatment. In all cases, neither the regions of dense tumor infiltration nor the adjacent CNS tissues revealed demyelination when using LFB/PAS histochemistry, indicating that infiltration by viable B lymphoma cells is not usually accompanied by demyelination (Supporting Information Figure S5 ).
DISCUSSION
CNS biopsies of patients with clinically suspected PCNSL can show a lack of neoplastic B cells and instead be characterized by inflammation and demyelination. Most often a clinical and pharmacological review of the cases reveals that steroids had been administered prior to biopsy acquisition. It has been suggested that the tissue features found in these biopsies may be indistinguishable from classical autoimmune inflammatory demyelinating diseases such as MS, although no studies specifically addressing this question have been reported (4, (14) (15) (16) . Moreover, the utility of molecular diagnostic approaches may be limited when no histological evidence of lymphoma cells is available, thus underscoring the importance of identifying histological hallmarks for the differential diagnosis of these two entities (4, 9) .
Here, we present the largest cohort thus far of histologically confirmed ST-PCNSL specimens without an identifiable neoplastic B cell population or apparent residua of lymphoma cells, and for the first time undertake a direct comparison with early MS lesions. Robust histological criteria could be identified, in particular the pattern of demyelination, the extent of lymphocyte infiltration and the presence of numerous apoptoses, all of which aid in the differential diagnosis of ST-PCNSL and autoimmune inflammatory demyelinating disorders (Table 2) .
Consistent with previous publications (2, 6, 7, 9, 12, (16) (17) (18) , we show that a histologically confirmed diffuse large B cell lymphoma can initially manifest as a demyelinating lesion with prominent inflammation and no evidence of lymphoma cells, a finding often referred to as 'sentinel lesion'. Most of the literature describes patients who, similar to our cohort, underwent corticosteroid therapy prior to biopsy acquisition, thus reinforcing the view that the sequential manifestation of demyelination and diffuse large B cell lymphoma could be related to the corticosteroid treatment (2, (7) (8) (9) 14) . Sentinel lesions have nonetheless also rarely been reported in the absence of documented corticosteroid treatment (2, 12) ; thus, the possibility of an underlying PCNSL should always be considered when suggestive clinical, radiological and pathological findings are present.
Demyelination, defined as the selective loss of myelin with preservation of the axonal lattice, is a histological feature that directs the neuropathologist to a limited number of differential diagnoses. The pattern of demyelination provides important clues for differentiating between the infectious, toxic and autoimmune diseases under consideration (6, 13) . In our study, early ST-PCNSL lesions, rich in MRP14 1 phagocytes, often showed a patchy and in part incomplete myelin loss, using myelin histochemistry as well as immunohistochemistry, and thus clearly contrasted with the confluent, near complete demyelination observed in MS lesions of similar lesion stage. Of note, the extent of demyelination observed in ST-PCNSL was even more prominent in LFB/PAS histochemistry than in MBP immunostaining, underlining the important myelin damage, but only partial myelin loss at this early stage of ST-PCNSL lesion development. Additionally, a clearly defined, macrophage-rich border of ongoing demyelination and macrophage recruitment was found to be a strong indication of MS rather than ST-PCNSL.
ST-PCNSL specimens frequently showed a thickening of the vessel walls and strong PAS staining, which was not observed in the MS lesions studied. This feature may indicate an accumulation of glycoproteins in the basal membrane of the lesional blood vessels, possibly related to intense endothelial activation and leakiness of the blood-brain barrier. Yet, its role in the pathophysiology of ST-PCNSL lesion formation remains to be determined.
In line with previous reports (9) we observed a distension of the underlying axonal lattice in demyelinated lesion areas in ST-PCNSL. Quantitatively, we determined that axonal density was reduced to about 40-50%, a level similar to that observed in early MS lesions. Also, a similar density of axonal spheroids was found in both entities, suggesting that the axonal damage observed is related to recent demyelination and not helpful for differentiating ST-PCNSL from MS.
The most striking quantitative difference between both entities was the increased amount of lymphocytic infiltration in ST-PCNSL, a feature that served as the sole diagnostic predictor between the two conditions in our cohort. Although significant differences were observed between MS and ST-PCNSL lesions regarding the cell density of CD8 1 and CD4 1 lymphocytes, the similarities in the CD4 to CD8 ratio and the high collinearity between candidate predictors (CD3, CD4, CD8 and Ki67) suggest that the density of CD4 1 and CD8 1 T cells was subordinate to the density of CD3 1 lymphocytes (see Supporting Information Appendix S1). As expected, both CD8 and CD4 also revealed a significant effect on diagnosis and served as independent predictors. Therefore, we propose that the amount of lymphocyte infiltration in a demyelinating biopsy specimen, in particular in elderly patients with relevant radiological features, should be considered a 'red flag' for a suspected ST-PCNSL, and thus prompt an inquiry about pre-biopsy steroid treatment and, consequently, close clinical follow-up.
At the lesion stage studied in this cohort, the distribution of T cells in MS lesions exhibited mostly a perivascular localization while in ST-PCNSL a more diffuse distribution was observed. However, T cell distribution may vary in the course of lesion evolution in MS and other inflammatory diseases. Whether similar changes in T cell distribution over time also occur in ST-PCNSL is unknown. The intense CD4-dominated T cell infiltration is at odds with the preceding steroid treatment and indicates a strong, rapid and thus most likely antigen-independent lymphocyte recruitment to the steroid-ablated lymphoma. The detailed mechanisms of steroid-induced lymphoma cell death remain to be determined, but induction of simultaneous apoptosis in a large number of tumor cells is assumed (20) . Interestingly, phagocytosis of apoptotic cells generally is accompanied by an anti-inflammatory macrophage response, leading to rapid removal of death cells without substantial tissue injury. In our study, massive macrophage infiltration in the ST-PCNSL cases was associated with myelin and axonal damage and an important infiltration of T cells, thus indicating a proinflammatory cyto-and chemokine environment. Molecular studies will need to address the nature of the inflammatory signalling cascades induced by steroid-induced lymphoma cell death.
In conclusion, when histological changes as described above are present, the neuropathologist should refrain from primarily considering autoimmune inflammatory demyelination and instigate a close follow-up of the patients and timely re-biopsy. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Figure S2 . Diffuse and perivascular macrophage infiltration in ST-PCNSL and MS. Representative microphotographs of two ST-PCNSL (A-H) and two MS lesions (I-P) stained for the panmacrophage marker KiM1P (brown) or MRP14 (red). In ST-PCNSL, the macrophages show a diffuse distribution but are also grouped around blood vessels (A and C). B and D. A fraction of the macrophages expresses the early macrophage invasion marker MRP14. E-H. High magnification images of the corresponding pictures above (A-D). I-P. Within MS lesions (I and K) the macrophage density is similar to that observed in ST-PCNSL, but appears to be increased at the actively demyelinating lesion border. J and L. The density of MRP14 expressing macrophages is higher at the lesion border. M-P. Corresponding high magnification images of panels I-L. Figure S3 . Histological confirmation of DLBCL. Representative microphotographs of the second biopsy 5 months after the initial diagnosis of an inflammatory demyelinating lesion (presented in Figure 1 ). Typical histological characteristics of a DLBCL such as hypercellularity with overt pleomorphism (A), abundant mitoses (B) and strong expression of CD20 (C) can be observed. Table S1 . Clinical characteristics of ST-PCNSL patients. Table S2 . Clinical characteristics of MS patients. Appendix S1.
